December 8, 2025- Special Meeting
The Maryland Prescription Drug Affordability Board invites you to attend the December Board Meeting, scheduled for Monday, December 8, 2025 at 9:00 AM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, December 3, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, December 3, 2025. Please utilize the subject line “December 2025 Board Comments.”
AGENDA AND MEETING MATERIALS:
Written Comment Packet
Written Comments were received from the following:
- Diabetes Patient Advocacy Coalition
- EACH/PIC Coalition
- Let My Doctors Decide Action Network
- Value of Care Coalition
November 17, 2025
The Maryland Prescription Drug Affordability Board invites you to attend the November Board Meeting, scheduled for:
November 17, 2025 — 10:00AM- 3:00PM
Scheduled Lunch Break from 12:00-1:00PM
Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed, registration is not required. You may also attend in person at the following address:
Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401
The meeting will be livestreamed at this link HERE when the meeting starts.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, November 12, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please include in the subject line: November 2025 Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, November 12, 2025.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
OZEMPIC DOSSIER INFORMATION* (POSTED 11/4/2025)- UPDATED (NEW)
*Also posted as meeting materials for the November 17, 2025 Board Meeting
TRULICITY DOSSIER INFORMATION* (POSTED 11/4/2025)- UPDATED (NEW)
*Also posted as meeting materials for the November 17, 2025 Board Meeting
Comments Received for the 11/17/2025 PDAB Meeting from the following:
- AARP
- AstraZeneca
- Boehringer Ingelheim
- Committee to Protect Healthcare
- Community Access National Network
- Diabetes Patient Advocacy Coalition
- EACH/PIC Coalition
- Larry Zarzecki
- Let My Doctors Decide Action Network
- Lilly
- Maryland Healthcare for All Coalition
- Maryland NARFE Federation
- Value of Care Coalition
September 29, 2025 (Rescheduled from September 15, 2025)
The Maryland Prescription Drug Affordability Board invites you to attend the September Board Meeting, scheduled for Monday, September 29, 2025 at 2:00 PM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, September 24, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, September 24, 2025. Please utilize the subject line “September 2025 Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
Written Comment Packet
Comments received from the following:
- Community Access National Network
- Diabetes Patient Advocacy Coalition
- EACH/PIC Coalition
- Let My Doctors Decide Action Network
- Maryland Tech Council
- Value of Care Coalition
July 28, 2025
The Maryland Prescription Drug Affordability Board invites you to attend the July Board Meeting, scheduled for Monday, July 28, 2025 at 2:00 pm. Part of the meeting may be conducted in closed session. Because the meeting will be livestreamed, registration is not required. You may also attend in person at the following address:
Miller Senate Building, William Amoss Room, 4th Floor
11 Bladen Street
Annapolis, MD 21401
The meeting will be livestreamed at this link HERE.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, July 23, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation and provide additional details.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please include in the subject line: July 2025 Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, July 23, 2025.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
DOSSIER INFORMATION (POSTED 7/18/2025)- UPDATED - FARXIGA
DOSSIER INFORMATION (POSTED 7/18/2025)- UPDATED- JARDIANCE
Written Comment Packet
- Comments Received from the following entities:
- Aimed Alliance
Diabetes Patient Advocacy Coalition
Let My Doctors Decide Action Network
The Board of Garrett County Commissioners
- Comments Received after the deadline
June 23, 2025- Special Meeting
The Maryland Prescription Drug Affordability Board invites you to attend the June Board Meeting, scheduled for Monday, June 23, 2025 at 9:00 AM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, June 18, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, June 18, 2025. Please utilize the subject line “June 2025 Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
May 19, 2025
The Maryland Prescription Drug Affordability Board invites you to attend the May Board Meeting, scheduled for Monday, May 19, 2025 at 2:00 PM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, May 14, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, May 14, 2025. Please utilize the subject line “May 2025 Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
- Written Comment Packet
Comments Received from the following entities: - AARP
- EACH/PIC Coalition
- HeathHIV
- Let My Doctors Decide Action Network
- Maryland Healthcare for All
- Timothy Joyce
- Value of Care Coalition
- Comments Received after the deadline
March 24, 2025
The Maryland Prescription Drug Affordability Board invites you to attend the March Board Meeting, scheduled for Monday, March 24, 2025 at 2:00 PM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, March 19, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, March 19, 2025. Please utilize the subject line “March 2025 Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
February 26, 2025- Ad-Hoc Meeting
The Maryland Prescription Drug Affordability Board invites you to attend the February Board Meeting, scheduled for Wednesday, February 26, 2025 at 8:00 AM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Friday, February 21, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Friday, February 21, 2025.. Please utilize the subject line “February 2025 Board Comments.”
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
JANUARY 27, 2025
The Maryland Prescription Drug Affordability Board invites you to attend the January Board Meeting, scheduled for Monday, January 27, 2025, at 2:00 pm. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
PUBLIC COMMENT: The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, January 22, 2025, and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
WRITTEN COMMENT: The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, January 22, 2025. Please utilize the subject line “Jan 2025 Board Comments.”
COST REVIEW STUDY PROCESS:
The Board invites public comment concerning Farxiga and Jardiance in connection with the cost review study. Under COMAR 14.01.04.05D, the Board may consider oral public comment made at the Board meeting, and written comments.
- If you wish to provide an oral comment at the January 27, 2025 meeting, please register to speak, at least 2 work days before the scheduled meeting (by Wednesday, January 22, 2025), in accordance with COMAR 14.01.01.05A. To register, please email [email protected] and provide (1) your name, (2) your address, and (3) the agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
- If you wish to provide written comments, please submit any comments and materials to [email protected], at least 2 work days before the scheduled meeting (by Wednesday, January 22, 2025), in accordance with COMAR 14.01.01.05B.
AGENDA AND MEETING MATERIALS: The meeting agenda and meeting materials will be posted on the Board Meetings page when available.
